European Commission approves Amgen's Blincyto and Biogen's Elocta; U.K. pledges £2B more in drug spending;

@FiercePharma: Japan's Takeda gets early U.S. FDA nod for ixazomib. More from FiercePharmaAsia | Follow @FiercePharma

@EricPFierce: ICYMI: Catalent halts production, calls authorities into French plant where tampering is suspected. Article | Follow @EricPFierce

@CarlyHFierce: With veteran job-choppers Pfizer and Allergan joining hands, how many layoffs are in the cards? More | Follow @CarlyHFierce

> About £2 billion of a £9 billion increase in healthcare spending next year pledged by the U.K. will be for drugs. Report

> Biogen ($BIIB) and Sobi's hemophilia A treatment Elocta has been approved by the European Commission. Release

> Amgen's ($AMGN) new treatment Blincyto has been approved in Europe for treatment of adults with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Release

> The CEO of an Irish company has said if politicians don't like tax inversion deals like Pfizer's ($PFE) buyout of Allergan ($AGN), they should stop complaining and change their tax laws. Report

Medical Device News

@FierceMedDev: Startup gets $36.5M to conduct U.S. pivotal trial for novel endoscopic weight loss device. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Physicians call for novel abuse-deterrent opioid agonist/antagonist formulations in survey. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Dell teams up with Zebra Medical Vision for data analytics initiative. Report | Follow @EmilyWFierce

> Dell teams up with Zebra Medical Vision for data analytics initiative. Story

> Cigna launches genetic counseling program for hereditary cancers. Article

Biotech News

@FierceBiotech: Genmab's lymphoma project flops in Phase III with Novartis holding the bag. Article | Follow @FierceBiotech

@JohnCFierce: Any journos who would like to attend our breakfast event on Big Data? Drop me a line @ [email protected] More info | Follow @JohnCFierce

@DamianFierce: Has anyone asked the presumptive FDA chief whether jet fuel can melt steel? More | Follow @DamianFierce

> FierceBiotech Radio on the ins and outs of 'Pfizergan' and whatever it is Martin Shkreli's doing. Listen | Subscribe

> BMS racks up another Opdivo approval after FDA makes quick decision. Report

> What if 21st Century Cures had been around before bapineuzumab blew up? Story

> XBiotech flubs a Phase III trial with its lead cancer drug. Article

Drug Delivery News

> Depomed acquires pain candidate for $25M as it fends off Horizon's hostile takeover. Item

> AstraZeneca begins dosing in trial of its Bind-partnered cancer candidate. More

> J&J leads $24M financing into maker of OTC 'liquid shots' for common ailments. Report

> Pills loaded with mucoadhesive patches could make oral insulin a reality. Story

> Adapt Pharma earns FDA approval of first intranasal spray for emergency opioid overdose. Article

Pharma Manufacturing News

> Novo Nordisk says all its manufacturing plants will run on renewable electricity by 2020. News

> Abzena to raise $30M to buy another U.S. contract drug developer. Report

> Some production resumes at Strides Shasun facility following fire that killed one. More

> Synerlab buys contract manufacturing developer Alcala Farma for undisclosed price. Story

> South Africa's Ascendis picks up manufacturing facility in $24.6M deal for Akacia. Article

Pharma Asia News

> India's Biocon chief says R&D tax breaks essential for investment. Story

> China's ZAI Lab in oncology license deal for HM61713 with South Korea's Hanmi. More

> India's gliptin market ready for a shakeup by Zydus at 11 U.S. cents a pill. Report

> Japan's Takeda gets early U.S. FDA nod for ixazomib. Item

> India-EU trade talks back on next year, GVK issue sidelined. Article

Suggested Articles

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.